The possibility of Gd deposition in the pediatric brain following exposure to GBCAs is a potentially serious issue. Our study of 34 pediatric patients that received between 5 and 15 administrations of low dose (0.05 mmol/kg bodyweight) gadobenate dimeglumine (MultiHance; Bracco) revealed no differences in T1-signal in the DN, GP, pons and thalamus relative to measurements made in 24 age- and weight-matched control subjects that had never been exposed to any GBCA. Likewise no meaningful differences were seen in DN–pons and GP–thalamus SI ratios. We consider low dose gadobenate to be safe and effective for diagnosis and routine follow-up of pediatric oncologic patients.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords